You’ve seen the ads. You’ve heard the celebrities. You’ve probably even heard your friends talking about their “Ozempic results.” But walk into any conversation about medical weight loss and confusion quickly sets in: Is semaglutide the same as Ozempic? Is Wegovy different? Which one should I ask my doctor about?
Here’s the short answer: Ozempic, Wegovy, and semaglutide are all the same active molecule — but they differ in dose, FDA approval, and intended use. Understanding the difference matters if you’re considering medicated weight loss with a physician-supervised program.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist — a drug that mimics a natural gut hormone called glucagon-like peptide-1. This hormone is released after eating and does several things:
- Signals the brain that you’re full (reduces appetite)
- Slows stomach emptying (you stay full longer)
- Regulates blood sugar (reduces insulin spikes)
- Acts on reward circuits in the brain (reduces food cravings)
The result is a powerful biological brake on overeating that works even when willpower doesn’t. For more on the mechanism, see how semaglutide works.
Semaglutide was developed by Danish pharmaceutical company Novo Nordisk and is now marketed under two brand names, depending on dose and indication.
Ozempic: Semaglutide for Diabetes
Ozempic is semaglutide at doses of 0.5mg, 1mg, or 2mg per week, injected subcutaneously. It was FDA-approved in 2017 for type 2 diabetes — specifically to lower blood sugar and reduce cardiovascular risk in adults with T2D.
Weight loss was noticed as a significant side effect in clinical trials, which is why it became so popular off-label for obesity — even though it wasn’t approved for that purpose. Ozempic’s maximum dose (2mg/week) is lower than the weight-loss-specific formulation, which limits its weight loss effectiveness compared to Wegovy.
Key facts about Ozempic:
- FDA-approved for: type 2 diabetes
- Dose: 0.5mg, 1mg, or 2mg per week
- Brand: Novo Nordisk
- Available as: weekly injection pen
- Insurance coverage: often covered for diabetes, rarely for weight loss
Wegovy: Semaglutide for Obesity
Wegovy is semaglutide at a higher dose — 2.4mg per week — FDA-approved in 2021 specifically for chronic weight management in adults with a BMI ≥30, or ≥27 with a weight-related condition (like high blood pressure or sleep apnea).
The SUSTAIN and STEP clinical trials showed Wegovy users losing an average of 15–17% of their body weight over 68 weeks — results unprecedented for a non-surgical weight loss medication.
Key facts about Wegovy:
- FDA-approved for: chronic weight management (obesity)
- Dose: titrates from 0.25mg up to 2.4mg per week over 16–20 weeks
- Brand: Novo Nordisk
- Insurance coverage: increasingly covered, but varies significantly
Compounded Semaglutide: The Third Option
During the brand-name shortages of 2023–2025, FDA-licensed compounding pharmacies were permitted to produce compounded semaglutide — essentially the same active ingredient, manufactured at a fraction of the cost.
Compounded semaglutide became the primary vehicle for physician-supervised weight loss programs across the country, including at many functional medicine practices in South Florida.
Key facts about compounded semaglutide:
- FDA shortage status allows compounding (check current status with your provider)
- Significantly lower cost than brand-name alternatives
- Same active molecule, typically available in higher dose concentrations
- Must be prescribed and supervised by a licensed physician
Side-by-Side Comparison
| Ozempic | Wegovy | Compounded Semaglutide | |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Semaglutide |
| Max weekly dose | 2mg | 2.4mg | Varies (per Rx) |
| FDA indication | Type 2 diabetes | Obesity/weight loss | Off-label |
| Average weight loss | 10–12% | 15–17% | Similar to Wegovy at same dose |
| Cost (without insurance) | $800–$1,000/mo | $1,300–$1,500/mo | $250–$500/mo |
| Availability | Improving | Improving | Available via compounding Rx |
Which One Is Right for You?
The answer depends on your health history, weight loss goals, and insurance coverage. This is a conversation to have with a board-certified physician — not a decision to make based on ads or social media.
At LifeBoost MD in Boca Raton, Dr. Bruce Stratt evaluates each patient individually, orders baseline labs, and designs a weight loss protocol matched to your physiology and goals. Whether that means Wegovy, compounded semaglutide, or a different approach altogether, the goal is the same: sustainable, physician-monitored weight loss that gets real results.
A free consultation is available — no obligation, no pressure. Book yours today.
Frequently Asked Questions
Ozempic is a brand name for semaglutide manufactured by Novo Nordisk and FDA-approved for type 2 diabetes. Semaglutide is the active ingredient in both Ozempic and Wegovy. They contain the same molecule but are dosed differently and approved for different indications.
No. Semaglutide is a prescription medication that requires evaluation by a licensed physician. However, compounded semaglutide (available during FDA shortage periods) has been widely prescribed off-label for weight loss. At LifeBoost MD, Dr. Stratt evaluates each patient to determine the safest, most appropriate formulation.
Clinical trials show average weight loss of 15–17% of body weight over 68 weeks with 2.4mg/week semaglutide. Individual results vary based on starting weight, diet adherence, and activity level. Most patients lose 1–2 lbs per week in the initial months.
Yes. LifeBoost MD in Boca Raton offers physician-supervised semaglutide weight loss programs. Dr. Bruce Stratt evaluates each patient, determines the appropriate formulation and dosing, and monitors progress throughout treatment. Free consultations are available.
Last reviewed: February 28, 2026